News In Brief

Tavenner confirmed as CMS chief. DePuy phases out metal hips. More news

Marilyn Tavenner, a former nurse and hospital administrator who has been serving as acting administrator of the CMS since December 2011, was formally confirmed by the full Senate on a bipartisan vote of 91 to 7 on May 15. Tavenner’s approval rating among both Democrats and Republicans has been high, and she easily went through Senate Finance Committee confirmation hearings last month. (See Also see "Bipartisan Support Of Tavenner For Official CMS Administrator Post Abounds At Confirmation Hearing" - Medtech Insight, 15 April, 2013..) But her confirmation was temporarily held up by Sen. Tom Harkin, D-Iowa, who was unhappy that the Obama administration announced plans to use funds earmarked for the Public Health and Prevention Program under the Affordable Care Act to help fund the effort to implement new health insurance exchanges also established by ACA. (See Also see "Friendly Fire? Tavenner Nomination Held Up By Sen. Harkin" - Medtech Insight, 29 April, 2013..) Tavenner has widespread support for the post among the provider and payer communities and the device industry. (See Also see "Support Gathers In Provider, Payer Community For Tavenner To Head CMS" - Medtech Insight, 5 December, 2011..) She is the first Senate-confirmed administrator to run CMS since Mark McClellan, who served under former President George W. Bush, left the agency in 2006. In terms of device-relevant issues, she has been cited as being potentially more supportive of telehealth and wireless health care services than prior administrators. (See Also see "Straube: CMS Resistant To Telehealth, But Potential Supporter Waits In The Wings" - Medtech Insight, 7 November, 2011..)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By 

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Q’Apel Medical Recalls, Discontinues Stroke Therapy System After FDA Warning Letter, Class I Designation

 

Q’Apel Medical has pulled its aspiration system for stroke thrombectomy from the market after concerns raised by the US FDA in a February warning letter.

‘The FDA Will Be Looking For Avenues To Regulate Laboratory Developed Tests’

 

The FDA's final LDT ruling was struck down in federal court last month. For now, diagnostic companies can commercialize under CLIA regulations or apply for FDA approval. McDermott and Tribun Health have shared insights on the risks, pros and cons of both regulatory routes.

Ireland’s Medtech Keeps Calm While Trump Covets Its Healthcare Industry

 

The Republic of Ireland’s record in life sciences is impressive. Decades of investment, education and training have been major winners for the country’s successful economy. But its success is drawing unwanted attention from the US. Trump wants “to have that.”